

Press release

For immediate release

Genomtec submits yet another patent application in the LAMP technology confirming implementation of its work plan dedicated to Genomtec ID

Wrocław, Poland - April 22, 2021 - Genomtec SA, listed on the Warsaw NewConnect Stock Exchange market, a medical technology company from the space of clinical diagnostics utilised in the Point-Of-Care testing - POCT and also rapid laboratory genetic testing, filed yet another significant patent application to The Polish Patent Office, Republic of Poland. The patent application concerns the proprietary set of primers, the diagnostic method and the reaction mixture composition for genetic diagnosis of MRSA (methicillin-resistant staphylococcus aureus) in the LAMP technique. The assay is part of the systemic infections diagnostic panel planned for Genomtec ID - a mobile genetic testing platform dedicated for doctor's office, ambulance, airport or pharmacy. In addition to methicillin-resistant staphylococcus aureus, the systemic infections panel also includes Lyme disease and meningitis.

Methicillin-resistant staphylococcal strains are a common cause of hospital-acquired infections and constitute a significant problem due to difficulties in treatment and rapid onset of disease and its progression. The type of resistance developed by microorganisms means that you lack susceptibility to all beta-lactam antibiotics - including penicillins, cephalosporins, monobactams and carbapenems.

- Infections caused by the MRSA strain are characterized by a higher death rate, as well as a longer patient's hospitalization time, and thus a higher cost of treatment. Therefore, the diagnosis of the MRSA strain, mainly to limit its spread, is an extremely important issue in medicine. The LAMP technology already enables fast and precise diagnostics, and Genomtec ID will accelerate it even more - said Miron Tokarski, co-founder and president of Genomtec.

According to market data, only in the USA, the costs of hospitalization of patients infected with MRSA amounts to about USD 10 billion per year, which means an average of about 60,000 USD per patient¹. The early detection of MRSA and the isolation of infected patients would allow faster treatment delivery and a significant reduction in hospitalisation costs.

In mid-March this year Genomtec has filed a patent application in Poland for the proprietary set of primers, the diagnostic method and the reaction mixture composition for genetic diagnosis of the bacterial sexually transmitted infections utilizing the LAMP method, which is included in the sexually transmitted diseases panel.

Genomtec already holds two patents and has filed 20 patent applications. The company holds, among others, a patent for a method and a diagnostic system using the contactless heating technique granted in the USA and Poland. At the same time, the company is waiting for the decision of the European

¹ [Medicare penalties for MRSA infections could cost some hospitals millions | FierceHealthcare](#)

Patent Office and local patent offices of China, Hong Kong, Japan, Brazil and Canada. In addition, Genomtec has filed patent applications concerning the contactless heating technique processed by the European Patent Office (EPO), the United States Patent and Trademark Office (USPTO), local offices in China and Japan. Additionally, yet another six assay mixtures covered by patent applications are being processed via the PCT path .

The company's flagship solution is the Genomtec ID, a mobile diagnostic system functioning on the basis of a microfluidic system and proprietary, patented SNAAT® technology. The innovative diagnostic platform will be able to carry out several tests from one sample simultaneously, for example determining the cause of respiratory tract infections or sexually transmitted diseases, even in 15 minutes. Genomtec ID will be used for diagnostics at the patients' point of care, e.g. doctor's offices, emergency department, or even a pharmacy.

#####

Dodatkowych informacji udzielą:

Genomtec S.A.
Magdalena Kicińska
+48 604 201 230
m.kicinska@genomtec.com

Genomtec S.A.
Charles Winiarski
+44 7972406384
bkc.winiarski@genomtec.com

About Genomtec S.A.

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus. Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent-protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Genomtec was founded in 2016. The headquarter of Genomtec SA is located in Wroclaw. The company has its offices also in the United Kingdom hiring mostly engineers and designers to commercialize Genomtec ID. The company is listed on Warsaw Stock Exchange in alternative trading system NewConnect since March 17, 2021. More information: www.genomtec.com